EE03147B1 - Kontrollitud vabanemisega preparaat ja selle valmistamismeetodid - Google Patents

Kontrollitud vabanemisega preparaat ja selle valmistamismeetodid

Info

Publication number
EE03147B1
EE03147B1 EE9400376A EE9400376A EE03147B1 EE 03147 B1 EE03147 B1 EE 03147B1 EE 9400376 A EE9400376 A EE 9400376A EE 9400376 A EE9400376 A EE 9400376A EE 03147 B1 EE03147 B1 EE 03147B1
Authority
EE
Estonia
Prior art keywords
preparation
morphine
controlled release
preparations
manufacture
Prior art date
Application number
EE9400376A
Other languages
English (en)
Estonian (et)
Inventor
Anneli Chefrad Maritta
Olsson Birgitta
Ragnarsson Gert
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20389415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03147(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE03147B1 publication Critical patent/EE03147B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EE9400376A 1993-03-30 1994-11-16 Kontrollitud vabanemisega preparaat ja selle valmistamismeetodid EE03147B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9301057A SE9301057L (sv) 1993-03-30 1993-03-30 Beredning med kontrollerad frisättning

Publications (1)

Publication Number Publication Date
EE03147B1 true EE03147B1 (et) 1999-02-15

Family

ID=20389415

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400376A EE03147B1 (et) 1993-03-30 1994-11-16 Kontrollitud vabanemisega preparaat ja selle valmistamismeetodid

Country Status (25)

Country Link
US (1) US5614218A (fr)
EP (1) EP0642335B2 (fr)
JP (1) JP4107678B2 (fr)
KR (1) KR100316206B1 (fr)
CN (1) CN1104891C (fr)
AT (1) ATE189771T1 (fr)
AU (1) AU680891C (fr)
CA (1) CA2135639C (fr)
CZ (1) CZ284924B6 (fr)
DE (1) DE69423028T3 (fr)
DK (1) DK0642335T4 (fr)
EE (1) EE03147B1 (fr)
ES (1) ES2144516T5 (fr)
FI (1) FI113743B (fr)
GR (1) GR3033325T3 (fr)
HU (1) HU227344B1 (fr)
LV (1) LV10684B (fr)
NO (1) NO310015B1 (fr)
NZ (1) NZ263632A (fr)
PL (1) PL175326B1 (fr)
PT (1) PT642335E (fr)
RU (1) RU2136283C1 (fr)
SE (1) SE9301057L (fr)
SK (1) SK280362B6 (fr)
WO (1) WO1994022431A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
AU735113C (en) * 1991-12-24 2007-06-14 Mundipharma Medical Gmbh Opioid formulations for treating pain
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
KR20130010512A (ko) 1999-10-29 2013-01-28 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR100960200B1 (ko) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
WO2003024430A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
WO2003077897A1 (fr) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Inhibiteurs de recaptage de 5-ht pour le traitement de syndromes de la douleur viscerale
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
CA2498798A1 (fr) * 2002-09-20 2004-04-01 Alpharma, Inc. Formulation opioides a liberation prolongee et procedes d'utilisation connexes
EP2422775A3 (fr) * 2002-09-20 2012-04-18 Alpharma, Inc. Séquestration de sous-unité et compositions et procédés associés
WO2004032854A2 (fr) * 2002-10-04 2004-04-22 Pharmacia Corporation Compositions pharmaceutiques pour le traitement de la maladie de parkinson
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
CA2513893A1 (fr) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale
EP2301526B1 (fr) 2003-03-26 2016-03-23 Egalet Ltd. Système de libération contrôlée de morphine
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1575565B1 (fr) * 2003-08-08 2010-01-06 Biovail Laboratories International Srl Comprime d'hydrochlorure de bupropion a liberation modifiee
EP1810678A1 (fr) 2006-01-19 2007-07-25 Holger Lars Hermann Utilisation de morphine et naloxone pour la substitution de médicaments
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
AU2008286914B2 (en) * 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
EP2448406B1 (fr) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
WO2010149169A2 (fr) 2009-06-24 2010-12-29 Egalet A/S Formulations à libération contrôlée
JP2013526523A (ja) 2010-05-11 2013-06-24 シマ ラブス インク. メトプロロールを含むアルコール耐性持続放出性経口剤形
AR082189A1 (es) 2010-07-06 2012-11-21 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas, procedimiento
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
EP2976082A4 (fr) 2013-03-15 2016-05-11 Inspirion Delivery Technologies Llc Compositions anti-abus et méthodes d'utilisation
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2016064873A1 (fr) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
CA2007181C (fr) * 1989-01-06 1998-11-24 Angelo Mario Morella Compose pharmaceutique a liberation continue
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation

Also Published As

Publication number Publication date
PL175326B1 (pl) 1998-12-31
EP0642335A1 (fr) 1995-03-15
DE69423028T2 (de) 2001-01-18
DK0642335T3 (da) 2000-07-24
CA2135639A1 (fr) 1994-10-13
DK0642335T4 (da) 2005-05-23
CN1104891C (zh) 2003-04-09
SK143794A3 (en) 1995-06-07
HU9403437D0 (en) 1995-02-28
PL306421A1 (en) 1995-04-03
EP0642335B1 (fr) 2000-02-16
DE69423028D1 (de) 2000-03-23
DE69423028T3 (de) 2006-07-20
AU680891C (en) 2002-01-03
SE9301057D0 (sv) 1993-03-30
CA2135639C (fr) 2006-02-07
AU680891B2 (en) 1997-08-14
US5614218A (en) 1997-03-25
ES2144516T5 (es) 2005-07-01
ES2144516T3 (es) 2000-06-16
NO944565L (no) 1994-11-29
HUT71417A (en) 1995-11-28
SK280362B6 (sk) 1999-12-10
CZ298694A3 (en) 1995-05-17
CN1106608A (zh) 1995-08-09
WO1994022431A1 (fr) 1994-10-13
HU227344B1 (en) 2011-04-28
LV10684B (en) 1996-02-20
NZ263632A (en) 1997-06-24
FI945621A (fi) 1994-11-29
RU94046147A (ru) 1996-11-10
PT642335E (pt) 2000-08-31
CZ284924B6 (cs) 1999-04-14
RU2136283C1 (ru) 1999-09-10
FI113743B (fi) 2004-06-15
SE9301057L (sv) 1994-10-01
ATE189771T1 (de) 2000-03-15
FI945621A0 (fi) 1994-11-29
KR100316206B1 (ko) 2002-11-09
JPH08501319A (ja) 1996-02-13
JP4107678B2 (ja) 2008-06-25
NO944565D0 (no) 1994-11-29
LV10684A (lv) 1995-06-20
NO310015B1 (no) 2001-05-07
EP0642335B2 (fr) 2005-01-19
AU6439394A (en) 1994-10-24
GR3033325T3 (en) 2000-09-29

Similar Documents

Publication Publication Date Title
EE03147B1 (et) Kontrollitud vabanemisega preparaat ja selle valmistamismeetodid
NZ508526A (en) Opioid formulations for treating pain
YU49495B (sh) Formulacije oksikodona sa kontrolisanim otpuštanjem i njihova upotreba
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
YU48583B (sh) Postupak za pripremanje formulacije u obliku pilule za oralno davanje
NO921875L (no) Metallpeptidpreparater og fremgangsmaater for aa stimulere haarvekst
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
ATE202926T1 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
GEP19991686B (en) Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
MY124465A (en) Reduction of infarct volume using citicoline
KR19990077143A (ko) 디오스게닌을 함유하는 조성물
GB1453034A (en) Pharmaceutical composition for treating spasticity
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
EP1197227A4 (fr) Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RU95100741A (ru) Способ лечения туберкулеза легких
Turkistani et al. Effect of sucralfate on procainamide absorption
RU94036344A (ru) Способ лечения спида
RU94045317A (ru) Способ лечения вилюйского энцефаломиелита
RU94020847A (ru) Транквилизирующее средство

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231